ClinicalTrials.gg
RecruitingNCT07734636APRES-AKIUpdated Sep 8, 2026

A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

A Phase 4 interventional study of Early RASi restart strategy and Usual Care in Acute Kidney Injury, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Acute Kidney Injury by University of California, San Francisco — 5 open to participants now, 6 under way, 1 of them phase 3. Acute Kidney Injury · University of California, San Francisco.

Planned enrollment
5th of 10
60 · median 55
Started
2026
with 2 others
Phase 4
3 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Acute Kidney Injury by University of California, San Francisco, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 4, and was the 11th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

5 of the 11 studies in Acute Kidney Injury by University of California, San Francisco are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acute Kidney Injury by University of California, San Francisco, or all of them as a file.
02

Study summary

The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care.

Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.

Read the detailed description

Among at-risk patients with heart failure and chronic kidney disease, use of RASi medications decreases the subsequent risk of adverse events such as cardiovascular death and kidney disease progression. However, RASi treatment is often stopped when AKI is detected in the hospital based on the notion that restoring an intact renin-angiotensin system in the context of hypovolemia or hypotension may be helpful to maintain perfusion to the glomeruli and thus support the glomerular filtration rate.

In observational studies, restart of RASi medications among at-risk patients after AKI has been associated with decreased subsequent rates of mortality, cardiovascular events, and kidney disease progression. However, there is no rigorous evidence from randomized trials to guide optimal strategy of RASi restart after AKI.

This is a pilot trial among hospitalized patients with AKI whose RASi were held to investigate the feasibility and tolerability of a strategy of early RASi restart (n=30) compared to usual care (n=30). This pilot trial will provide valuable data critical to inform the design of a larger definitive trial.

The study hypothesis is that the strategy of early RASi restart after AKI is feasible and well-tolerated. This pilot trial will inform the design of a larger definitive trial to determine whether early RASi restart can increase rates of RASi use at 90 days compared to usual care.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Acute kidney injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease)
  • RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr)
  • AKI in recovery (defined by a decrease in SCr by ≥0.3mg/dL from peak)

Exclusion criteria

Exclusion Criteria:

  • RASi allergy or (i.e., angioedema, bilateral renal artery stenosis)
  • Ongoing dialysis requirement
  • Pregnant or breastfeeding
  • Prisoner
  • Palliative or hospice care involvement
  • Unable to consent
  • No enteral route of medication administration
  • Clinician judgment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Usual care

    RASi restart will be deferred to the study participant's providers.

    Drug: Usual Care

  • Experimental
    Early RASi restart strategy

    The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg/dL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq/L, SCr-based eGFR reported as ≥15 mL/min/1.73m2, and average systolic blood pressure≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.

    Drug: Early RASi restart strategy

Interventions

  • DrugEarly RASi restart strategy

    The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg/dL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq/L, CKD-EPI SCr-based eGFR reported as ≥15 mL/min/1.73m2, and average SBP ≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.

    Also known as: renin-angiotensin system inhibitors

  • DrugUsual Care

    RASi restart will be deferred to the study participant's providers.

06

What researchers measure

Primary outcomes

  1. Feasibility- RASi use separation

    Proportion of patients in the early RASi restart arm and the usual care arm who restart RASi within 72 hours of SCr downtrending by ≥0.3mg/dL from peak SCr and at hospital discharge

    Time frame: From date of enrollment until date of hospital discharge or up to 90 days if remains in the hospital

Secondary outcomes

  1. Tolerability- 90 day follow up completion

    Proportion of participants who complete 90 day follow up

    Time frame: Up to 90 days

  2. Tolerability- Lab evaluation post RASi

    Proportion with potassium and SCr evaluations within 1-2 weeks of RASi restart

    Time frame: Up to 2 weeks post hospital discharge or 90 days if patient remains in the hospital

  3. Tolerability- SCr evaluation after hospital discharge

    Proportion with SCr evaluation after hospital discharge

    Time frame: Up to 90 days

  4. Tolerability- Proteinuria evaluation

    Proportion with proteinuria evaluation after hospital discharge

    Time frame: Up to 90 days

Other outcomes

  1. Screening-to-recruitment ratio

    Number of patients screened divided by the number of patients enrolled

    Time frame: Total study duration, anticipated 2.5 years, up to 4 years total

  2. Adverse events

    Total number of adverse events and number of adverse events attributable to study intervention. Adverse events include: hyperkalemia (\>5.5mEq/L and \>6mEq/L), recurrent AKI (minor (30-\<50% decline) versus major (\>=50% decline) in eGFR), symptomatic hypotension or hypertension, emergency room visits, hospitalizations, increase index hospital length of stay

    Time frame: Up to 90 days

  3. 90 day RASi use

    Proportion with RASi use at 90 days

    Time frame: Up to 90 days

  4. Cumulative RASi exposure

    Number of days with RASi use

    Time frame: Up to 90 days

  5. Days to RASi restart

    Days to RASi restart from day of peak SCr

    Time frame: Up to 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data collected after deidentification

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2029, 30 months after the start.

Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 30 months is close to that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 29, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07734636
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 1, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Yuenting D Kwong, MD MAS
Contact
diana.kwong@ucsf.edu
415-514-7371
Yuenting D Kwong, MD MAS
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion